HeartBeam (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses. The transaction, completed on April 16, 2026, was supported by key stakeholders including ClearCardio, company leadership and institutional investors. Proceeds will fund commercialization of HeartBeam’s FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection technologies, expansion of AI capabilities and general corporate purposes.
This capital raise is significant for HeartBeam as it advances toward bringing its innovative cardiac monitoring technology to market. The company’s 3D ECG technology, which received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis in December 2025, represents a potential shift in how cardiac conditions are detected and monitored. The cable-free device collects ECG signals in 3D from three non-coplanar directions and synthesizes them into a standard 12-lead ECG, aiming to enable portable cardiac monitoring outside medical facilities.
With over 20 issued patents, HeartBeam is positioning itself in the growing remote cardiac monitoring market. The funding will support commercialization efforts and continued development of extended-wear patch technology, which could allow for longer-term monitoring, as well as AI-driven analytics to improve detection of acute cardiac events.
The offering’s support from ClearCardio and institutional investors signals confidence in HeartBeam’s technology and market potential. However, the company faces risks common to medical device startups, including regulatory hurdles, competition and adoption barriers. As noted in the company’s SEC filings, forward-looking statements involve uncertainties that could affect actual results.
For more details on the offering, visit https://ibn.fm/9iNYY. Further updates on HeartBeam are available in the company’s newsroom at https://ibn.fm/BEAT.
